University of Miami | Bascom Palmer Eye Institute

Research site

(Unclaimed)

Location

1638 NW 10th Avenue, Room 201-A, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

APL-2

LX201

Linsitinib

GT005

Pegcetacoplan

Ripasudil

Bevacizumab

AU-011

Lidocaine

Parent organization

This site is a part of University of Miami

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 88 total trials

A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were...

Enrolling

Thyroid Diseases

Graves Ophthalmopathy

Drug: linsitinib

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) (LIDS)

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twi...

Active, not recruiting

Thyroid Diseases

Graves Ophthalmopathy

Drug: Placebo

Drug: Linsitinib

Locations recently updated

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling

Indeterminate Lesions

Ocular Melanoma

Device: Suprachoroidal Microinjector

Drug: Bel-sar

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a...

Invitation-only

X-Linked Retinitis Pigmentosa

Biological: AGTC-501 (high dose and modified corticosteroid regimen)

Biological: AGTC-501 (high dose and standard corticosteroid regimen)

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Enrolling

Fuchs Endothelial Corneal Dystrophy

Drug: Ripasudil

Drug: Placebo

Locations recently updated

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease (spiriTED)

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight...

Enrolling

Thyroid Eye Disease

Other: Placebo

Drug: TOUR006 - 50 MG

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.

Enrolling

Fuchs Endothelial Corneal Dystrophy

Drug: Placebo

Drug: Ripasudil

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).

Enrolling

X-linked Retinoschisis

Biological: ATSN-201

New

Phase 2 Dose Escalation of Bel-sar With Suprachoroidal Injection in Subjects With Choroidal Metastasis From Breast or Lung Tumors

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with choroidal metastasis from breast or lung primary...

Begins enrollment this month

Eye Cancer

Lung Cancer

Drug: AU-011

Device: SCS Microinjector

PRIMA US-Feasibility Study in Atrophic Dry AMD (PRIMA-FS-US)

In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry...

Active, not recruiting

Dry Age-related Macular Degeneration

Device: PRIMA

Single Ascending Dose Study in Participants With LCA10

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal i...

Active, not recruiting

Eye Diseases, Hereditary

Inherited Retinal Dystrophies

Drug: EDIT-101

Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease (GARDian)

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease.This is a multicenter study, which will be conducted in...

Enrolling

Stargardt Disease

Genetic: OCU410ST

Locations recently updated

Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human cl...

Enrolling

Cone Rod Dystrophy

Stargardt Disease

Drug: ACDN-01

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of...

Active, not recruiting

Thyroid Eye Disease

Drug: Teprotumumab

Drug: Placebo